Texas Biotech, Mitsubishi Chemical Corp. deal

TXB said partner Mitsubishi received Japanese approval for its Novastan brand of argatroban to treat acute cerebral infarction (acute ischemic stroke). TXB is conducting Phase III trials of argatroban in North America as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT). TXB expects to file an NDA mid-1997. TXB also is conducting a Phase II trial of the product as an adjunctive treatment for use in thrombolytic therapy in acute myocardial infarction. ...